FVFIGP
CARM

Flagship Ventures Fund IV General Partner’s Carisma Therapeutics CARM Stock Holding History

Flagship Ventures Fund IV General Partner’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$2.46M Buy
+73,321
New +$1.86M 0.42% 5
2015
Q4 		$4.41M Buy
+73,321
New +$4.16M 0.87% 3

Other funds holding CARM

FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Flagship Ventures Fund IV General Partner's CARM Position: Q2 2016 in Review

Flagship Ventures Fund IV General Partner opened a new position in Carisma Therapeutics (CARM) in Q2 2016: 73,321 shares worth $2.46M. The stake represents 0.42% of the portfolio and ranks #5 among its holdings. This is a return to the name: Flagship Ventures Fund IV General Partner previously reported a position in CARM as recently as Q4 2015.

Flagship Ventures Fund IV General Partner first reported a position in CARM in Q4 2015 and has held it in 2 quarters since. The position peaked at $4.41M in Q4 2015. 25 funds tracked by Wall St. Rank hold CARM as of Q2 2016.

  • Flagship Ventures Fund IV General Partner held 73,321 shares of Carisma Therapeutics worth $2.46M as of Q2 2016.
  • Carisma Therapeutics was a new Flagship Ventures Fund IV General Partner position in Q2 2016.
  • Carisma Therapeutics made up 0.42% of Flagship Ventures Fund IV General Partner's portfolio in Q2 2016, its #5 holding.
  • Flagship Ventures Fund IV General Partner first reported a position in Carisma Therapeutics in Q4 2015 and has held it in 2 quarters since.
  • Flagship Ventures Fund IV General Partner's Carisma Therapeutics position peaked at $4.41M in Q4 2015.
  • 25 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2016.

Based on Flagship Ventures Fund IV General Partner's 13F filing for Q2 2016, filed 15 Aug 2016.